anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject suppressant capable of suppressing the oxidative decomposition of endogenous or exogenous melatonin in vivo and enhancing the stability and utilization efficiency of the melatonin in vivo by including a lignan compound in a sesame seed and an antioxidant. SOLUTION: This suppressant contains (A) sesamine and/or its analog and (B) an antioxidant (preferably vitamin E). The ratio of the ingredient B based on the ingredient A is preferably >=0.001 and <=1,000. A mixture of the suppressant with melatonin can be used as a combined pharmaceutical preparation having enhanced hypnotic actions of the melatonin. The mixing ratio of the mixture to the melatonin is preferably >=1 and >=100. The suppressant can be used in the form of a kit pharmaceutical preparation with the melatonin pharmaceutical preparation. Thereby, the hypnotic actions of the melatonin can be enhanced and the suppressant can be utilized as a food and drink, etc., without any anxiety about adverse effects.
Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
BACKGROUND: Intracerebral hemorrhage (ICH) is a stroke subtype characterized by high mortality and complex post-event complications. Research has extensively covered the acute phase of ICH; however, ICU readmission determinants remain less explored. Utilizing the MIMIC-III and MIMIC-IV databases, this investigation develops machine learning (ML) models to anticipate ICU readmissions in ICH patients.
METHODS: Retrospective data from 2242 ICH patients were evaluated using ICD-9 codes. Recursive feature elimination with cross-validation (RFECV) discerned significant predictors of ICU readmissions. Four ML models-AdaBoost, RandomForest, LightGBM, and XGBoost-underwent development and rigorous validation. SHapley Additive exPlanations (SHAP) elucidated the effect of distinct features on model outcomes.
RESULTS: ICU readmission rates were 9.6% for MIMIC-III and 10.6% for MIMIC-IV. The LightGBM model, with an AUC of 0.736 (95% CI: 0.668-0.801), surpassed other models in validation datasets. SHAP analysis revealed hydrocephalus, sex, neutrophils, Glasgow Coma Scale (GCS), specific oxygen saturation (SpO2) levels, and creatinine as significant predictors of readmission.
CONCLUSION: The LightGBM model demonstrates considerable potential in predicting ICU readmissions for ICH patients, highlighting the importance of certain clinical predictors. This research contributes to optimizing patient care and ICU resource management. Further prospective studies are warranted to corroborate and enhance these predictive insights for clinical utilization.
This Registry was designed to assure that the benefits and knowledge gained by studying clinical outcomes associated with the use of percutaneous orthopedic procedures outweigh the potential risks to the patients. The primary objective of this Registry is to observe the improvements in subject-reported clinical outcomes for these procedures used to treat musculoskeletal disorders. Secondary objectives include evaluating post-treatment complication, adverse events, re-injections, and surgical intervention. Patients receiving percutaneous orthopedic treatments are asked to enroll before receiving treatment and complete a set of baseline questionnaires regarding pain and functionality of the area of the body being treated (i.e. knee, shoulder, spine, etc). Follow-up outcomes are collected at 1 month, 3 months, 6 months, 12 months, 18 months, and annually 2-20 years post-injection. Subjects are withdrawn from the Registry prematurely if a surgical operation occurs.
All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
Aripiprazole is a psychotropic drug that is available as aripiprazole oral solution. Aripiprazole is 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. The molecular formula is C23H27Cl2N3O2 and its molecular weight is 448.38. The chemical structure is:

Aripiprazole oral solution is a clear, colorless to light-yellow solution available in a concentration of 1 mg/mL. The inactive ingredients for this solution include edetate disodium, fructose, glycerin, hydrochloric acid, methylparaben, propylene glycol, propylparaben, purified water, sodium hydroxide pellets and sucrose. The oral solution is flavored with orange flavor which containing benzyl alcohol and propylene glycol.
At least 1 in 4 of the 700,000 U.S. Veterans who served in the 1990-1991 Gulf War suffer from Gulf War Illness (GWI). Despite considerable research, effective treatments remain elusive. GWI refers to a complex of symptoms that typically include widespread chronic pain, persistent headache, memory and concentration problems, gastrointestinal difficulties, sleep disturbances and unexplained fatigue. This symptom profile is similar to that of fibromyalgia syndrome (FMS), a multi-symptom condition similar to GWI. Whereas, effective treatments for GWI have yet to be found, progress has been made in identifying medications to treat FMS. For example, the FDA has approved a number of medications including Duloxetine and Pregabalin for the treatment of FMS. Compared to placebo (PBO) Duloxetine (a serotonin norepinephrine reuptake inhibitor) and Pregabalin (an alpha-2-alpha-subunit calcium-channel ligand) significantly improved pain responses and fatigue. The capacity of Duloxetine to increase central levels of serotonin and norepinephrine as well as the more complex alterations of neurotransmitters and central nervous system (CNS) mediators of pain attributed to pregabalin are thought to be responsible for the medication's effects on pain, mood and sleep. Clinical practice and one open-label trial support the use of these medications in combination to achieve optimal symptom improvement amongst GWI sufferers; however, such combinations have not been formally tested in randomized controlled trials. The lack of progress in finding effective treatments for GWI, and the similarities between GWI and FMS, provides a rationale for determining if these FDA approved medications can provide significant symptomatic relief to Veterans who suffer from GWI. Central Texas is home to one of the highest number of Gulf War Veterans in the nation, thus the investigators' research team is ideally situated to conduct the proposed study. In a randomized, double-blind, controlled trial, 180 Veterans who meet defining criteria for GWI and whose symptom profile includes chronic widespread pain and sleep disturbances will be treated with one of the following medications; 1) AM Duloxetine+ PM placebo (PBO); 2) PM Pregabalin + AM PBO or 3) AM PBO + PM PBO. All active treatments will titrate from a lower dose in 2-week increments to the full therapeutic doses (FDA-approved for FMS). The outcome of the PBO double-dummy period will be compared statistically with 18 weeks of active therapy (weeks 5-22).
The investigators developed a multi-faceted knowledge translation intervention called The CARD System to provide a framework for delivering vaccinations at school that integrates evidence-based strategies to mitigate pain, fear and fainting and promotes a student-centred approach to vaccination. CARD addresses 2 components of the vaccination delivery program: 1) pre-vaccination day preparation and 2) vaccination day activities. In a small controlled clinical trial in a public health unit in Niagara, Ontario, the investigators demonstrated benefits of CARD on student symptoms during vaccination, including fear, and dizziness-precursor of fainting, and satisfaction with CARD by all stakeholder groups (students, public health staff, school staff and parents). This study will evaluate CARD in a large cluster trial in Calgary, Alberta. This trial is the final phase of a 3-phase project, whereby the first 2 phases involve developing an implementation plan for the local context and evaluating feasibility of implementation.

Eight community health centres that provide vaccination services to schools in their regions will be randomized in a 1:1 ratio to CARD or control (usual practices). Data will be collected for vaccination services carried out in grade 6 and grade 9 students in participating schools for the academic year 2019-2020.
Ethanol is the most commonly encountered substance in forensic toxicology. Determining blood alcohol concentration (BAC) in autopsies accounts for the majority of work in forensic diagnosis. The most common method to assess BAC is the enzymatic oxidation method because of its low cost, easy operation, and high throughput. Still, the elevated lactate and lactate dehydrogenase (LDH) levels in postmortem blood may affect accuracy. This study uses headspace gas chromatography with a flame ionization detector (HS-GC/FID) to assess the interference of lactate and LDH levels on BAC in 110 autopsied blood samples determined by the enzymatic oxidation method. The results showed that lactate and LDH levels in postmortem blood were higher than in normal blood. There was a weak correlation between the lactate levels and BAC difference (r = 0.23, p < 0.05) and a strong correlation between LDH levels and BAC difference (r = 0.67, p < 0.001). The differentiation of BAC between the enzymatic oxidation method and HS-GC/FID was significant (p < 0.001), confirming the interference significantly. All postmortem blood samples with lactate and LDH levels higher than regular lead to a positive error in determining BAC by enzymatic oxidation method. The study results suggest that the HS-GC/FID method should be used to determine BAC in postmortem blood samples instead of the enzymatic oxidation method to avoid mistakes in forensic diagnosis.
This is a randomized, multicenter observational study to assess the impact of the EDCS in a rheumatology clinical practice setting on patient satisfaction with patient-physician communication using the Health Tracker electronic data capture system . Patients will be randomly assigned in a 2:1 ratio to the Health Tracker-user or non-user groups, respectively. The primary outcomes of this study will be the impact that information gathered and analyzed by an electronic data capture system has on patient satisfaction with arthritis care and patient physician interactions in clinical practice. Patient satisfaction will be assessed using a questionnaire developed specifically for this study.

This study does not involve the use of any investigational drugs, and the protocol does not mandate the treatment regimen patients will receive. Physicians will prescribe antirheumatic medications in accordance with usual clinical practice. The planned duration of subject participation is 12 months
Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. Hypercalcemia may occur during treatment with calcium acetate. Mild hypercalcemia (Ca>10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12 mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate induced hypercalcemia. The long-term effect of calcium acetate on the progression of vascular or soft-tissue calcification has not been determined. Isolated cases of pruritus have been reported which may represent allergic reactions.
It has long been the practice to incorporate bactericides, fungicides and virucides in detergent compositions. But in such detergent modifications if the antimicrobial is washed off as the hands or other surfaces are rinsed, the effectiveness of the detergent is greatly reduced. The composition should be absorbed onto the skin or other surface being washed, leaving a film which resists removal by running water. This is termed substantivity. Cinnamon oils and similar antimicrobial cinnamic compounds have been in soaps but they rinse off. A cinnamic compound-containing antimicrobial surfactant is provided herein which is rendered substantive to the surface being washed.
The invention provides loaded platelets that include an absorbed loading vehicle having associated diagnostic or therapeutic agents. A method of loading platelets with diagnostic or therapeutic agents is provided. The method includes combining a loading vehicle having associated diagnostics or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets. Also provided is a method of targeting diagnostic or therapeutic agents to platelet localizing areas. The method includes the steps of: (a) combining a loading vehicle having associated diagnostic or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets; (b) isolating the platelets from excess loading vehicle; and (c) administering the isolated platelets to an animal in an effective concentration so as to promote targeting of the isolated platelets to platelet localizing areas. A method of imaging is also provided.
The invention discloses a cervical vertebra health-care product and a cervical vertebra health-care instrument matched with the cervical vertebra health-care product. The cervical vertebra health-care product comprises root of kudzu vine, radix paeoniae alba, red sage root, mint, cortex eucommiae, safflower and rhizome of Chinese galangal. The cervical vertebra health-care instrument matched with the cervical vertebra health-care product comprises a support, hollow balls and electrothermal sheets. The hollow balls are installed on the support in rows. The electrothermal sheets are installed on four sides of the support. Each one of the electrothermal sheets is coated with a heat-conducting membrane. Electromagnetic rods are installed around the support. Through the cervical vertebra health-care product and the cervical vertebra health-care instrument matched with the cervical vertebra health-care product, full cervical vertebra health care is realized in the daily life and cervical vertebra diseases are prevented effectively.
FSH preparation suitable for parenteral administration characterized biologically by a potency of at least 1350% and preferably 1600-1800% Standard (as defined in the Specification) and characterized chemically by a molecular weight less than 50,000 and preferably about 30,000, a cystine content of at least 4.5% and preferably 5.5-6.5% by weight, a carbohydrate content of at least 3% and preferably 5.5% by weight comprising at least 2% and preferably 3% by weight of hexose and at least 1% and preferably 2.5% by weight of hexosamine.  Detachable carbohydrates in the FSH product are mannose, galactose and fucose.  Product prepared by contacting an FSH-containing solution with a cellulose anion exchanger at a pH of at least 5.0-5.5 and a molarity of less than 0.1 or preferably pH 6.0-8.5 and molarity less than 0.02 and eluting the adsorbate with an aqueous solution of pH 3.5-4.8 or pH 5.0-5.5 or pH 6.0-8.5 and molarity at least 0.01.  Desirably the aqueous solution of FSH-containing material is treated to a preliminary alcoholic fractionation or preliminary proteolysis with trypsin, chymotrypsin or preferably pancreatin which may be followed by alcoholic fractionation or dialysis against water.  Salts employed to obtain the critical molarity of adsorption and desorption are sodium and potassium chloride, phosphate, hypophosphate.  Specified anionic exchangers are dimethyl-aminoethyl cellulose, diethylaminoethyl cellulose.  Specifications 758,751 and 862,180 are referred to.
Lung volume reduction surgery primarily increases vital capacity by reducing RV more than TLC. As the chest wall is the major TLC limiting factor, an alternative approach that could circumvent size mismatch would be a surgical enlargement of the thorax cavity. Any post-operative increase of TLC would allow greater dynamic operational lung volumes to occur with an equal amount of dead space. Moreover, resizing of the thorax would have a tremendous advantage over resizing of the lung, in that it would not require resection of the lung in patients in whom lung tissue is already scarce. Chest expansion will only be guaranteed if the sternal widening osteotomy will obtain a solid union. Small poly-ether-ether-keton (PEEK) cages were designed to match both sternal halves in a 'press fit' way, which were filled with lyophilised bone and fixed with extra wires as in a classical sternotomy. These bone-filled cages function as a perfect matrix for progressive in-growth of cancellous bone.
PROBLEM TO BE SOLVED: To obtain the subject composition which is effective for lowering the level of a phosphate in a serum without increasing the absorption of calcium, aluminum, and so on, by including a (co)polymer having specific repeating units. SOLUTION: This medicinal composition contains a (co)polymer having repeating units of formulas I to IV [(n) is an integer; R, R1 and R2 are each a lower alkyl or the like; X is a substitutable negative counterion (for example, chloride ion)] or the like, [for example, poly(allylamine) hydrochloride], which is preferably cross-linked with a cross-linking agent (for example, epichlorohydrin). The (co)polymer is obtained, for example, by adding 1 to 100 pts. of epichlorohydrin to a solution containing 100 pts. of polyethyleneimine and then heating the mixture to accelerate the reaction. The cross-linking agent is preferably used in an amount of about 0.5 to 75 wt.% based on the composition.
Of the total number of patients who received amlodipine besylate and benazepril hydrochloride in U.S. clinical studies of amlodipine besylate and benazepril hydrochloride, over 19% were 65 or older while about 2% were 75 or older. Overall differences in effectiveness or safety were not observed between these patients and younger patients. Clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Benazepril and benazeprilat are substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Amlodipine is extensively metabolized in the liver. In the elderly, clearance of amlodipine is decreased with resulting increases in peak plasma levels, elimination half-life and area-under-the-plasma-concentration curve. Thus a lower starting dose may be required in older patients [see Dosage and Administration (2)].
The invention discloses a developing embolism material and a preparation method thereof. The developable barium alginate embolism microsphere coated with the in-situ synthesized barium sulfate particles is prepared by adopting an electrostatic spraying technology in one step, so that the integration of a developer and an embolism material is realized, and the problems of difficult indirect development and rechecking and the like in the clinical use of interventional therapy are solved. The electrostatic spraying parameters are regulated and controlled to obtain monodisperse microspheres with the particle size of 100-1000 microns, so that the composite material is suitable for vascular embolization with different calibers. The contrast agent barium sulfate and the barium alginate microspheres are formed simultaneously, and barium sulfate particles are uniformly distributed in the microspheres and are firmly fixed. In vitro simulation experiments prove that the developing microspheres are very stable in the test time of 50 days. The great ear rabbit right renal artery embolism experiment proves that the developing microsphere has good developing effect and embolism effect. The electrostatic spraying technology has the characteristics of simplicity, rapidness and low cost, so that the one-step preparation method has the potential of production.
INTRODUCTION: Risky sexual behavior exposes an individual to the risk of contracting sexually transmitted infections including human immunodeficiency virus (HIV). Even though risky sexual behavior is a devastating problem in low- and middle-income countries, studies on risky sexual behavior and associated factors among reproductive-age women in Eastern African countries are limited. Therefore, this study aimed to assess the magnitude of risky sexual behavior and associated factors among reproductive-age women in Eastern African countries that help to target high-risk groups and set appropriate intervention.
METHOD: The appended and recent Demographic and Health Survey dataset of 10 Eastern African countries from 2012 to 2022 was used for data analysis. A total of 111,895 participants were included in this study as a weighted sample. Associated factors were determined using a multilevel mixed-effects logistic regression model. Significant factors in the multilevel mixed-effect logistic regression model were declared significant at p-values < 0.05. The adjusted odds ratio (AOR) and confidence interval (CI) were used to interpret the results.
RESULT: The overall magnitude of risky sexual behavior among reproductive-age women in Eastern African countries was 28.16% (95% CI 27.90%, 28.43%), which ranged from 3.80% in Ethiopia to 67.13% in Kenya. In the multivariable analysis, being a younger woman, being an educated woman, being tested for human immunodeficiency virus, having work, drinking alcohol, and being an urban dweller were factors that were significantly associated with higher odds of risky sexual behavior.
CONCLUSION: The overall magnitude of risky sexual behavior among reproductive-age women in Eastern African countries was high. Individual-level (being a younger woman, being an educated woman, being tested for human immunodeficiency virus, having work, and drinking alcohol) and community-level (being an urban dweller) variables were associated with higher odds of risky sexual behavior. Therefore, policymakers and other stakeholders should give special consideration to urban dwellers, educated, worker and younger women. Better to improve the healthy behavior of women by minimizing alcohol consumption and strengthening HIV testing and counseling services to reduce the magnitude of risky sexual behavior.